Gland pharma share price

• Home • Karnataka Election 2023 • Budget 2023 • Market • Stock Stats • Top Gainers • Top Losers • Indices • Nifty 50 • Sensex • CaFE Invest • Commodities • IPO NEWS • Investing Abroad • IPOs • Economy • Tech • Auto • SME • Mobility • Industry • Banking & Finance • Education • Money • Insurance • Income Tax • Mutual Funds • Blockchain • Infrastructure • Railways • Aviation • Roadways • India • Defence • Lifestyle • Travel & Tourism • Health • Science • Healthcare • Brand Wagon • Entertainment • Events • Jobs • Sports • IPL 2023 • Multimedia • Photos • Videos • Audio • Web Stories • Auto Web Stories • Infographics • ePaper • Today’s Paper • From The Print • International • Edits & Columns • Opinion • FE 360 • Politics • Economy • Personal Finance Print • Front Page • FE Insight • Fe@Campus • archive Gland Pharma share price surged as high as 9.6 per cent to a fresh 52-week high of Rs 3,061 apiece in intraday on BSE, after the company posted a 34 per cent on-year rise in consolidated net profit to Rs 260.4 crore in Jan-Mar quarter of FY21. Gland Pharma shares made a market debut in November 2020 and were listed at Rs 1,701, as against the IPO price of Rs 1,500. The stock has zoomed 80 per cent from the listing price, while it has more than doubled from the issue price. After a stellar IPO, strong sectoral buying in pharma with steady Q4 results have led to Gland pharma crossing Rs 3,000 to an all-time high. “Technically, daily closing above 3055 should lead to a higher targe...

Gland Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Gland Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/275344/gland-pharma-ltd/ Get Gland Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business Gland Pharma Limited, a generic injectable-focused company, engages in the development, manufacture, sale, and distribution of pharmaceuticals. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products for various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, as well as anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business-to-business model in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Gland Pharma Ltd. Gland Pharma announced Q4FY23 & FY23 results: • Revenue from operations for FY23, at Rs 36,246 million declined by 18% as compared to the previous year Rs 44,007 million. • Revenue from operations during Q4FY23 has declined at Rs 7,850 million by 29% as compared to the corresponding quarter of the previous year Rs 11,030 million. • Sale to US market is comprising of products sold to both US customers and Indian customers for US markets. For Q4FY23 direct sale to US customers Rs 4,233 million and to Indian customers for US markets was Rs 578 million, totalling Rs 4,808 million. • During the quarter the Company has Launched 10 product SKUs. • Rest of the World markets, accounted for 22% of Q4FY23 revenue for the quarter. • EBITDA of Rs 10,248 million in FY23, as compared to Rs 15,102 million for the previous financial year, a decrease of 32%. • The total R&D expense for Q4FY23 was Rs 678 million which is 8.6% of revenue. During the year financial year, the Company has incurred Rs 2,014 million in R&D which is 5.6% of revenue. • During Q4FY23, the Company has filed 9 ANDAs, and received 7 ANDA approvals. • As on March 31, 2023, we along with our partners has 334 ANDA filings in the United States, of which 263 were approved and 71 pending approvals. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We have formally closed the acquisition of Cenexi and welcome it to be a part of the...

• The company has shown a good profit growth of 38.9429011883194% for the Past 3 years. • The company has shown a good revenue growth of 29.1214518083462% for the Past 3 years. • Company has been maintaining healthy ROE of 21.1328771168802% over the past 3 years. • Company has been maintaining healthy ROCE of 27.8464718538104% over the past 3 years. • Company is virtually debt free. • Company has a healthy Interest coverage ratio of 309.977671755725. • The Company has been maintaining an effective average operating margins of 35.1485560845307% in the last 5 years. • Company has a healthy liquidity position with current ratio of 10.0430819831013. • The company has a high promoter holding of 57.86%. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 1103.01 856.9 1048.31 925.9 785.42 Total Expenditure 754.58 586.7 753.07 641.94 616.27 Operating Profit 348.43 270.2 295.24 283.96 169.15 Other Income 65.23 74.39 65.62 61.51 38.94 Interest 2.03 0.9 1.72 2.62 2.18 Depreciation 31.08 34.91 36.67 37.61 37.54 Exceptional Items 0 0 0 0 -56.46 Profit Before Tax 380.56 308.78 322.47 305.24 111.91 Tax 94.58 79.33 82.84 77.7 32.7 Profit After Tax 285.98 229.45 239.63 227.54 79.21 Adjusted EPS (Rs) 17.41 13.94 14.55 13.82 4.81 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 1619.94 2044.2 2633.24 3462.88 4400.71 Total Expenditure 1084.84 1337.89 1677.77 2160.61 2...

Global research and broking firm Bernstein has assessed the market share and growth of Gland Pharma's top 10 molecules. Noting that the drugmaker's top three molecules, namely, Daptomycin, Micafungin, and Enoxaparin have improved market shares in recent months, Bernstein retained its 'outperform' call on the stock. "For most of the top 10 molecules, we see partner market shares for Gland being stable or recovering from a trough," Bernstein stated in its report. Highlighting a positive trend in terms of market share growth for major molecules, the broking firm assigned a price target of Rs 1,702 for Gland Pharma, which indicates an upside potential of over 71 percent from the scrip's closing price on June 13. On June 13, shares of Gland Pharma settled 4 percent higher at Rs 993.70 on the National Stock Exchange. The sharp gains in the stock were also triggered by Bernstein's expectations of bullish upside potential. Aside from an increase in market share for the top three molecules, the broking firm revealed that shares for Heparin, a drug used to decrease the clotting ability of the blood and help prevent harmful clots from forming in blood vessels seem to have stabilised and will depend on supply issue resolution. As for other molecules like Cisatracurium (used in anaesthesia to provide skeletal muscle relaxation) and Ziprasidone (used to treat schizophrenia and bipolar mania) also the broking firm saw a slow increase in market share. "Meanwhile, for molecules like Levoth...

STOCK SUMMARY • Face Value (₹) 1.00 • Beta 0.14 • 52-Week Low (₹) 861.00 • 52-Week High (₹) 2,730.45 • Price-to-Book (X)* 2.09 • Dividend Yield (%) 0.00 • Price-to-Earnings (P/E) (X)* 20.21 • Earnings Per Share (₹) 49.95 • Sector Price Earning (X)* 30.33 • Market Cap (₹ Cr.)* 16,619.14 • * Vaues as of last close price The peers of Gland Pharma Ltd are Biocon Ltd, Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Lupin Ltd, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd, Syngene International Ltd, Laurus Labs Ltd, Divis Laboratories Ltd, Sun Pharmaceuticals Industries Ltd, Dr Reddys Laboratories Ltd, Zydus Lifesciences Ltd, Cipla Ltd, Glaxosmithkline Pharmaceuticals Ltd. Gland Pharma Ltd, incorporated in the year 1978, has its registered office in Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043, 91-40-30510999, 91-40-30510800. The main industry in which Gland Pharma Ltd operates is Pharmaceuticals - Indian - Bulk Drugs. Auditor/Auditors for Gland Pharma Ltd is/are S R Batliboi & Associates LLP. In the main management, Yiu Kwan Stanley Lau is chairman and SAMPATH KUMAR PALLERLAMUDI is the company secretary for Gland Pharma Ltd. • CSNM C S N Murthy Independent Director • SS SRINIVAS SADU Managing Director & CEO • EGV ESSAJI GOOLAM VAHANVATI Independent Director • QC QIYU CHEN Director • YKSL Yiu Kwan Stanley Lau Chairman & Independent Directo • SKP SAMPATH KUMAR PALLERLAMUDI Company Sec. & Compli. Officer • NLK Naina Lal Kidwai Independent...

• Gland Pharma among 7 stocks that saw significant decline from 52-week highs News • Stock market update: Nifty Pharma index advances 0.68% in an upbeat market News • Jupiter Wagons, Faze Three among top smallcap additions by MFs in May; Dollar Industries, Sirca Paints major exits News • Announcements NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 21.28 2.09 9.81 13.89 8.89 11.59 30.85 21.54 47.44 9.46 0.00 0.00 25.08 4.90 19.56 24.37 10.31 28.36 21.09 13.18 14.69 1.42 0.49 0.00 31.42 3.83 11.07 13.41 6.35 16.25 11.75 8.23 15.04 0.88 0.58 0.00 32.01 5.55 17.35 21.21 12.56 12.61 20.06 15.71 45.89 2.49 0.00 0.00 39.58 3.15 8.06 11.59 5.46 10.43 12.66 7.87 18.58 2.87 0.25 0.00 Add More About Gland Pharma Gland Pharma Ltd., incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 16,609.25 Crore) operating in Pharmaceuticals sector. Gland Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Export Incentives for the year ending 31-Mar-2022. For the quarter ended 31-03-2023, the company has reported a Consolidated Total Income of Rs 823.95 Crore, down 17.59 % from last quarter Total Income of Rs 999.80 Crore and down 29.47 % from last year same quarter Total Income of Rs 1,168.25 Crore. Company has reported net profit after tax of Rs 78.68 Crore in latest quarter. The company’s top management includes Mr.Yiu Kwan Stanley Lau, Mr.Srinivas ...

STOCK SUMMARY • Face Value (₹) 1.00 • Beta 0.14 • 52-Week Low (₹) 861.00 • 52-Week High (₹) 2,718.00 • Price-to-Book (X)* 2.09 • Dividend Yield (%) 0.00 • Price-to-Earnings (P/E) (X)* 20.21 • Earnings Per Share (₹) 49.95 • Sector Price Earning (X)* 30.33 • Market Cap (₹ Cr.)* 16,619.14 • * Vaues as of last close price COMPETITORS • Zydus Lifesciences ₹551.05 1.90 (0.35%) • Aurobindo Pharma ₹682.60 -2.80 (0.41%) • Dr Reddys Laboratories ₹4,915.05 111.60 (2.32%) • Lupin ₹830.45 -4.30 (0.52%) • Divis Laboratories ₹3,579.60 -1.45 (0.04%) • Alkem Laboratories ₹3,398.95 4.55 (0.13%) • Sun Pharmaceuticals Industries ₹992.00 3.60 (0.36%) The peers of Gland Pharma Ltd are Zydus Lifesciences Ltd, Aurobindo Pharma Ltd, Dr Reddys Laboratories Ltd, Lupin Ltd, Divis Laboratories Ltd, Alkem Laboratories Ltd, Sun Pharmaceuticals Industries Ltd, Syngene International Ltd, Biocon Ltd, Laurus Labs Ltd, Torrent Pharmaceuticals Ltd, Ajanta Pharma Ltd, Cipla Ltd, Glaxosmithkline Pharmaceuticals Ltd. Gland Pharma Ltd, incorporated in the year 1978, has its registered office in Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad, Telangana, 500043, 91-40-30510999, 91-40-30510800. The main industry in which Gland Pharma Ltd operates is Pharmaceuticals - Indian - Bulk Drugs. Auditor/Auditors for Gland Pharma Ltd is/are S R Batliboi & Associates LLP. In the main management, Yiu Kwan Stanley Lau is chairman and SAMPATH KUMAR PALLERLAMUDI is the company secretary for Gland Pharma Ltd...

Si haces clic en « Aceptar todo», nosotros y • mostrar anuncios y contenido personalizados basados en perfiles de interés; • medir la efectividad de los anuncios y el contenido personalizados, y • desarrollar y mejorar nuestros productos y servicios. Si no quieres que nosotros ni nuestros socios utilicemos cookies y datos personales para estos propósitos adicionales, haz clic en « Rechazar todo». Si quieres personalizar tus opciones, haz clic en « Gestionar configuración de privacidad». Puedes cambiar tus opciones en cualquier momento haciendo clic en el enlace «Configuración de privacidad y cookies» o «Panel de control de privacidad» de nuestros sitios y aplicaciones. Para obtener más información sobre cómo utilizamos tus datos personales, consulta nuestra

Q4FY23 Quarterly & FY23 Annual Result Announced for Gland Pharma Ltd. Gland Pharma announced Q4FY23 & FY23 results: • Revenue from operations for FY23, at Rs 36,246 million declined by 18% as compared to the previous year Rs 44,007 million. • Revenue from operations during Q4FY23 has declined at Rs 7,850 million by 29% as compared to the corresponding quarter of the previous year Rs 11,030 million. • Sale to US market is comprising of products sold to both US customers and Indian customers for US markets. For Q4FY23 direct sale to US customers Rs 4,233 million and to Indian customers for US markets was Rs 578 million, totalling Rs 4,808 million. • During the quarter the Company has Launched 10 product SKUs. • Rest of the World markets, accounted for 22% of Q4FY23 revenue for the quarter. • EBITDA of Rs 10,248 million in FY23, as compared to Rs 15,102 million for the previous financial year, a decrease of 32%. • The total R&D expense for Q4FY23 was Rs 678 million which is 8.6% of revenue. During the year financial year, the Company has incurred Rs 2,014 million in R&D which is 5.6% of revenue. • During Q4FY23, the Company has filed 9 ANDAs, and received 7 ANDA approvals. • As on March 31, 2023, we along with our partners has 334 ANDA filings in the United States, of which 263 were approved and 71 pending approvals. Commenting on the results, Mr. Srinivas Sadu, MD & CEO of Gland Pharma said “We have formally closed the acquisition of Cenexi and welcome it to be a part of the...